Cempra to Present at Two Upcoming Investor Conferences

CHAPEL HILL, N.C., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in two upcoming investor conferences. Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra, will provide a company overview and update on its clinical development programs.

• Stifel 2015 Healthcare Conference, The New York Palace Hotel, New York, November 17, 2015 at 10:15 a.m. ET.
• Jefferies Autumn 2015 Global Healthcare Conference in London, The May Fair Hotel, London, November 19, 2015 at 4:40 p.m. GMT (11:40 a.m. ET).

A live audio webcast and archive of the presentations will be available on the company website at http://investor.cempra.com/events.cfm. Listeners are encouraged to visit the site prior to the scheduled presentation to register, download and install any necessary audio software.

About Cempra, Inc.

Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates are currently in advanced clinical development. Solithromycin (CEM-101) has successfully completed two Phase 3 clinical trials for community-acquired bacterial pneumonia (CABP) and is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan. Solithromycin is also in a Phase 3 clinical trial for uncomplicated bacterial urethritis caused by Neisseria gonorrhoeae and chlamydia. Cempra is contracted with BARDA for the development of solithromycin for pediatric use. Three formulations, intravenous, oral capsules and a suspension formulation are in a Phase 1b trial in children from birth to 17 years of age. Taksta™ is Cempra's second product candidate, which is being developed for acute bacterial skin and skin structure Infections (ABSSSI) and is also expected to be tested in an exploratory study for chronic oral treatment of refractory infections in bones and joints. Both products seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra has also synthesized novel macrolides for non-antibiotic uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Cempra was founded in 2006 and is headquartered in Chapel Hill, N.C. For additional information about Cempra please visit www.cempra.com.

CONTACT: Investor Contact:
         Robert H. Uhl
         Westwicke Partners, LLC
         (858) 356-5932
         [email protected]

         Media Contact:
         Tony Plohoros
         6 Degrees
         (908) 591-2839
         [email protected]

You May Also Be Interested In

• Jefferies cuts Apple rating as higher-priced iPhone roadmap looks difficult
• Adventour Launches Expanded 2026 Corporate Packages After 18 Years
• Align Technology Prevails in China Patent Infringement Action Against Angelalign